Regulatory and Administrative Components of an IND Application (5/14) REdI 2017

Published 2020-08-06

Recommendations

31:21

Benefit-Risk Considerations in Drug Development (6/14) REdI 2017
46:00

Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017
33:18

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018
39:14

Formal Meetings for PDUFA Products and Communication Best Practices (4of14) REdI 2018
1:23:58

Statistical Considerations for Premarketing Risk Assessment
3:01:55

Facilitating Generic Drug Product Development through Product-Specific Guidances
2:26:13

Redesigned Pre-Submission Meetings in GDUFA III: Benefits for ANDA Submission and Approval
04:34

Expanded Access Part 2: How to Submit a Single Patient IND
23:33

LACF and Acidified Foods Regulations and Requirements
7:00:43

185th Meeting of Vaccines and Related Biological Products Advisory Committee
6:04:12

REdI Annual Conference 2024: CBER (Biologics) Innovation in Medical Product Development (Day 1 of 2)
7:42:03

REdI Annual Conference 2024: CBER (Biologics) Innovation in Medical Product Development (Day 2 of 2)
01:31

Gene Therapy Inside Out
05:28

Episode 5 - On The Road with Jim Jones - April 2024
01:33

Can Cardiac "Organ on a Chip" Technology Help Drug Toxicology Researchers? | Researching FDA
7:13:56

REdI Annual Conference 2024: CDER (Drugs) Innovation in Medical Product Development (Day 2 of 2)
01:48

The Future of Clinical Trials, The Real Cost Campaign, and Sun Safety Tips | FDA In Your Day Ep. 5
7:33:16

May 24, 2024 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
00:26

Waterproof Sunscreen? Sun Safety Tips from Episode 5 of FDA In Your Day | Full Video on Channel
7:35:04

REdI Annual Conference 2024: CDER (Drugs) Innovation in Medical Product Development (Day 1 of 2)

Similar videos